A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO
OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS
WITH MODERATELY TO SEVERELY ACTIVE CROHN¿S DISEASE AND OBESITY OR OVERWEIGHT
- Registry ID
- I6T-MC-AMCE
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2026-06-29
- Last update
- 2025-05-22
Conditions
- CROHN'S DISEASE
- OVERWEIGHT/OBESITY
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY {VESPER 6)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, AND ACTIVE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-78934804 IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
- A PHASE II, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, 42-WEEK DOSE-FINDING TRIAL FOR BI 3034701 ADMINISTERED SUBCUTANEOUSLY COMPARED TO PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT
- A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF ELECOGLIPRON IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS (EMBOLD)
- A MASTER PROTOCOL FOR PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA, AND OBESITY OR OVERWEIGHT (ENLIGHTEN-3)
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES
View on source registry